BioCentury
ARTICLE | Clinical News

Avastin bevacizumab: Phase III

July 21, 2003 7:00 AM UTC

Results from the previously reported U.S. Phase III trial showed the median survival for the 100 patients given Avastin plus 5-FU/leucovorin was 18.3 months. Patients given Avastin plus irinotecan/5-F...